RxDoctor Payments Data

Kristina Truong

Family Medicine · Austin, TXNPI 1043707102

Payments from drug & device makers

$2,827in general payments, 2019–2025

Across 145 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$523
  • Lilly USA, LLC$481
  • Boehringer Ingelheim$336
  • Astellas Pharma US Inc$185
  • Dynavax Technologies Corporation$183
  • GSK$147
  • plus $972 from 21 others

What the payments were for

  • Food & beverage$2,827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,827 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$30,622
Medicare patients
125
Services billed
845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide18$23,689
EliquisApixaban15$16,925
JardianceEmpagliflozin12$15,443
Spiriva HandihalerTiotropium Bromide12$5,964
Atorvastatin Calcium197$1,814
Gabapentin67$1,718
Levothyroxine Sodium111$1,711
Losartan Potassium126$1,390
Fluoxetine Hcl52$1,166
Estradiol17$1,017
Lisinopril101$762
Bupropion XlBupropion Hcl39$732
Albuterol Sulfate HfaAlbuterol Sulfate41$730
Nifedipine ErNifedipine17$707
Rosuvastatin Calcium66$700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$523$23,68918 claims
PfizerEliquis$74$16,92515 claims
Boehringer IngelheimJardiance$336$15,44312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →